{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:15Z","timestamp":1790959335406,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95583-w","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:40:55Z","timestamp":1743388855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differential association between cumulative dose of 5\u03b1-reductase inhibitors and mortality"],"prefix":"10.1038","volume":"15","author":[{"given":"Jinhyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-Yong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Cheol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"95583_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jdv.14624","volume":"32","author":"V Kanti","year":"2018","unstructured":"Kanti, V. et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J. Eur. Acad. Dermatol. Venereol. 32, 11\u201322. https:\/\/doi.org\/10.1111\/jdv.14624 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"95583_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40257-014-0077-5","volume":"15","author":"S Varothai","year":"2014","unstructured":"Varothai, S. & Bergfeld, W. F. Androgenetic alopecia: an evidence-based treatment update. Am. J. Clin. Dermatol. 15, 217\u2013230. https:\/\/doi.org\/10.1007\/s40257-014-0077-5 (2014).","journal-title":"Am. J. Clin. Dermatol."},{"key":"95583_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1210\/jcem.74.3.1371291","volume":"74","author":"JD McConnell","year":"1992","unstructured":"McConnell, J. D. et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 74, 505\u2013508. https:\/\/doi.org\/10.1210\/jcem.74.3.1371291 (1992).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 1","key":"95583_CR4","first-page":"29","volume":"76","author":"JD McConnell","year":"1995","unstructured":"McConnell, J. D. Benign prostatic hyperplasia: treatment guidelines and patient classification. Br. J. Urol. 76 (Suppl 1), 29\u201346 (1995).","journal-title":"Br. J. Urol."},{"key":"95583_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/smrj.3","volume":"1","author":"L Trost","year":"2013","unstructured":"Trost, L., Saitz, T. R. & Hellstrom, W. J. Side effects of 5-Alpha reductase inhibitors: A comprehensive review. Sex. Med. Rev. 1, 24\u201341. https:\/\/doi.org\/10.1002\/smrj.3 (2013).","journal-title":"Sex. Med. Rev."},{"key":"95583_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/tau-22-690","volume":"12","author":"B Chislett","year":"2023","unstructured":"Chislett, B. et al. 5-alpha reductase inhibitors use in prostatic disease and beyond. Transl Androl. Urol. 12, 487\u2013496. https:\/\/doi.org\/10.21037\/tau-22-690 (2023).","journal-title":"Transl Androl. Urol."},{"key":"95583_CR7","first-page":"56","volume":"9","author":"JM Hirshburg","year":"2016","unstructured":"Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C. & Reichenberg, J. S. Adverse effects and safety of 5-alpha reductase inhibitors (Finasteride, Dutasteride): A Systematic Review. J. Clin. Aesthet. Dermatol. 9, 56\u201362 (2016).","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"95583_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jamainternmed.2019.0280","volume":"179","author":"RR Sarkar","year":"2019","unstructured":"Sarkar, R. R. et al. Association of treatment with 5alpha-Reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern. Med. 179, 812\u2013819. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0280 (2019).","journal-title":"JAMA Intern. Med."},{"key":"95583_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.urology.2018.05.033","volume":"119","author":"LP Wallner","year":"2018","unstructured":"Wallner, L. P. et al. The use of 5-Alpha reductase inhibitors to manage benign prostatic hyperplasia and the risk of All-cause mortality. Urology 119, 70\u201378. https:\/\/doi.org\/10.1016\/j.urology.2018.05.033 (2018).","journal-title":"Urology"},{"key":"95583_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamaoncol.2015.0387","volume":"1","author":"L Azoulay","year":"2015","unstructured":"Azoulay, L., Eberg, M., Benayoun, S. & Pollak, M. 5alpha-Reductase inhibitors and the risk of cancer-Related mortality in men with prostate cancer. JAMA Oncol. 1, 314\u2013320. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0387 (2015).","journal-title":"JAMA Oncol."},{"key":"95583_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00345-020-03202-2","volume":"39","author":"PG Knijnik","year":"2021","unstructured":"Knijnik, P. G. et al. The impact of 5-alpha-reductase inhibitors on mortality in a prostate cancer chemoprevention setting: a meta-analysis. World J. Urol. 39, 365\u2013376. https:\/\/doi.org\/10.1007\/s00345-020-03202-2 (2021).","journal-title":"World J. Urol."},{"key":"95583_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamaoncol.2022.1501","volume":"8","author":"L Bjornebo","year":"2022","unstructured":"Bjornebo, L. et al. Association of 5alpha-Reductase inhibitors with prostate cancer mortality. JAMA Oncol. 8, 1019\u20131026. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1501 (2022).","journal-title":"JAMA Oncol."},{"key":"95583_CR13","doi-asserted-by":"crossref","unstructured":"13. Lee, J., Lee, J. S., Park, S. H., Shin, S. A. & Kim, K. Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int. J. Epidemiol. 46, e15 https:\/\/doi.org\/10.1093\/ije\/dyv319 (2017).","DOI":"10.1093\/ije\/dyv319"},{"key":"95583_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-5-5","volume":"5","author":"V Essebag","year":"2005","unstructured":"Essebag, V., Platt, R. W., Abrahamowicz, M. & Pilote, L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med. Res. Methodol. 5, 1\u20136 (2005).","journal-title":"BMC Med. Res. Methodol."},{"key":"95583_CR15","volume-title":"Global recommendations on physical activity for health","author":"World Health Organization, t","year":"2010","unstructured":"World Health Organization, t. Global recommendations on physical activity for health (World Health Organization, 2010)."},{"key":"95583_CR16","doi-asserted-by":"crossref","unstructured":"Ainsworth, B. E. et al. Compendium of Physical Activities: a second update of codes and MET values. Med. Sci. Sports Exerc. 43, 1575\u20131581 (2011). (2011).","DOI":"10.1249\/MSS.0b013e31821ece12"},{"key":"95583_CR17","unstructured":"Nicholas, P. J. & Boca, R. Statistics for epidemiology. Danvers: Chapman Hall\/CRC (2003)."},{"key":"95583_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/EDE.0000000000000221","volume":"26","author":"S Suissa","year":"2015","unstructured":"Suissa, S. Brief report: the Quasi-cohort approach in pharmacoepidemiology: upgrading the nested Case\u2013Control. Epidemiology 26, 242\u2013246 (2015).","journal-title":"Epidemiology"},{"key":"95583_CR19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ije\/dys147","volume":"41","author":"JP Vandenbroucke","year":"2012","unstructured":"Vandenbroucke, J. P. & Pearce, N. Case\u2013control studies: basic concepts. Int. J. Epidemiol. 41, 1480\u20131489 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"95583_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.aje.a116206","volume":"135","author":"M Maclure","year":"1992","unstructured":"Maclure, M. & Greenland, S. Tests for trend and dose response: misinterpretations and alternatives. Am. J. Epidemiol. 135, 96\u2013104. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a116206 (1992).","journal-title":"Am. J. Epidemiol."},{"key":"95583_CR21","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1210\/jc.2013-3576","volume":"99","author":"MM Shores","year":"2014","unstructured":"Shores, M. M. et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J. Clin. Endocrinol. Metab. 99, 2061\u20132068. https:\/\/doi.org\/10.1210\/jc.2013-3576 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"95583_CR22","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1210\/jc.2013-3272","volume":"99","author":"BB Yeap","year":"2014","unstructured":"Yeap, B. B. et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J. Clin. Endocrinol. Metabolism. 99, E9\u2013E18 (2014).","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"95583_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0039-128x","volume":"63","author":"MC Uygur","year":"1998","unstructured":"Uygur, M. C., Arik, A. I., Altug, U. & Erol, D. Effects of the 5\u03b1-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance:: A prospective clinical study. Steroids 63, 208\u2013213. https:\/\/doi.org\/10.1016\/S0039-128x (1998). (98)00005\u2009\u2013\u20091.","journal-title":"Steroids"},{"key":"95583_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/s0090-4295(02)01905-2","volume":"60","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn, C. G. et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60, 434\u2013441. https:\/\/doi.org\/10.1016\/s0090-4295(02)01905-2 (2002).","journal-title":"Urology"},{"key":"95583_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jama.2012.227","volume":"307","author":"S Bhasin","year":"2012","unstructured":"Bhasin, S. et al. Effect of testosterone supplementation with and without a dual 5\u03b1-Reductase inhibitor on Fat-Free mass in men with suppressed testosterone production A randomized controlled trial. JAMA 307, 931\u2013939. https:\/\/doi.org\/10.1001\/jama.2012.227 (2012).","journal-title":"JAMA"},{"key":"95583_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","volume":"63","author":"DW Russell","year":"1994","unstructured":"Russell, D. W. & Wilson, J. D. Steroid 5\u03b1-reductase: two genes\/two enzymes. Annu. Rev. Biochem. 63, 25\u201361 (1994).","journal-title":"Annu. Rev. Biochem."},{"key":"95583_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/PSY.0000000000000784","volume":"82","author":"JA Kim","year":"2020","unstructured":"Kim, J. A., Choi, D., Choi, S., Chang, J. & Park, S. M. The association of 5alpha-Reductase inhibitor with suicidality. Psychosom. Med. 82, 331\u2013336. https:\/\/doi.org\/10.1097\/PSY.0000000000000784 (2020).","journal-title":"Psychosom. Med."},{"key":"95583_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","volume":"177","author":"B Welk","year":"2017","unstructured":"Welk, B. et al. Association of suicidality and depression with 5alpha-Reductase inhibitors. JAMA Intern. Med. 177, 683\u2013691. https:\/\/doi.org\/10.1001\/jamainternmed.2017.0089 (2017).","journal-title":"JAMA Intern. Med."},{"key":"95583_CR29","doi-asserted-by":"publisher","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","volume":"5","author":"M Garcia-Argibay","year":"2022","unstructured":"Garcia-Argibay, M., Hiyoshi, A., Fall, K. & Montgomery, S. Association of 5alpha-Reductase inhibitors with dementia, depression, and suicide. JAMA Netw. Open. 5, e2248135. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48135 (2022).","journal-title":"JAMA Netw. Open."},{"key":"95583_CR30","doi-asserted-by":"publisher","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","volume":"5","author":"M Garcia-Argibay","year":"2022","unstructured":"Garcia-Argibay, M., Hiyoshi, A., Fall, K. & Montgomery, S. Association of 5\u03b1-reductase inhibitors with dementia, depression, and suicide. JAMA Netw. Open. 5, e2248135\u2013e2248135 (2022).","journal-title":"JAMA Netw. Open."},{"key":"95583_CR31","doi-asserted-by":"publisher","first-page":"djw168","DOI":"10.1093\/jnci\/djw168","volume":"108","author":"JM Unger","year":"2016","unstructured":"Unger, J. M. et al. Long-term consequences of finasteride vs placebo in the prostate cancer prevention trial. JNCI: J. Natl. Cancer Inst. 108, djw168 (2016).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"95583_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1346-8138.2002.tb00200.x","volume":"29","author":"G Altomare","year":"2002","unstructured":"Altomare, G. & Capella, G. L. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J. Dermatol. 29, 665\u2013669. https:\/\/doi.org\/10.1111\/j.1346-8138.2002.tb00200.x (2002).","journal-title":"J. Dermatol."},{"key":"95583_CR33","doi-asserted-by":"crossref","unstructured":"Doherty, N. et al. Use of 5\u2010alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: A population\u2010based cohort study. Int. J. Cancer 155, 666\u2013674 (2024).","DOI":"10.1002\/ijc.34937"},{"key":"95583_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamapsychiatry.2018.4513","volume":"76","author":"NM Melhem","year":"2019","unstructured":"Melhem, N. M. et al. Severity and variability of depression symptoms predicting suicide attempt in High-Risk individuals. JAMA Psychiatry. 76, 603\u2013613. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4513 (2019).","journal-title":"JAMA Psychiatry"},{"key":"95583_CR35","doi-asserted-by":"publisher","first-page":"19786","DOI":"10.1074\/jbc.C109.016931","volume":"284","author":"JE Drury","year":"2009","unstructured":"Drury, J. E., Di Costanzo, L., Penning, T. M. & Christianson, D. W. Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J. Biol. Chem. 284, 19786\u201319790. https:\/\/doi.org\/10.1074\/jbc.C109.016931 (2009).","journal-title":"J. Biol. Chem."},{"key":"95583_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1527-3458.2006.00053.x","volume":"12","author":"DA Finn","year":"2006","unstructured":"Finn, D. A. et al. A new look at the 5\u03b1-reductase inhibitor finasteride. CNS Drug Rev. 12, 53\u201376. https:\/\/doi.org\/10.1111\/j.1527-3458.2006.00053.x (2006).","journal-title":"CNS Drug Rev."},{"issue":"Suppl 1","key":"95583_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.psyneuen.2009.08.009","volume":"34","author":"JJ Lambert","year":"2009","unstructured":"Lambert, J. J., Cooper, M. A., Simmons, R. D., Weir, C. J. & Belelli, D. Neurosteroids: endogenous allosteric modulators of GABA(A) receptors. Psychoneuroendocrinology 34 (Suppl 1), 48\u201358. https:\/\/doi.org\/10.1016\/j.psyneuen.2009.08.009 (2009).","journal-title":"Psychoneuroendocrinology"},{"key":"95583_CR38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.amjmed.2023.06.021","volume":"136","author":"HT Ayele","year":"2023","unstructured":"Ayele, H. T. et al. The cardiovascular safety of Five-Alpha-Reductase inhibitors among men with benign prostatic hyperplasia: A Population-Based cohort study. Am. J. Med. 136, 1000\u20131010. https:\/\/doi.org\/10.1016\/j.amjmed.2023.06.021 (2023).","journal-title":"Am. J. Med."},{"key":"95583_CR39","doi-asserted-by":"publisher","first-page":"e0119694","DOI":"10.1371\/journal.pone.0119694","volume":"10","author":"TF Hsieh","year":"2015","unstructured":"Hsieh, T. F. et al. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One. 10, e0119694 (2015).","journal-title":"PLoS One"},{"key":"95583_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/er.2016-1067","volume":"38","author":"RS Swerdloff","year":"2017","unstructured":"Swerdloff, R. S. et al. Biochemistry, physiology, and clinical implications of elevated blood levels. Endocr. Rev. 38, 220\u2013254. https:\/\/doi.org\/10.1210\/er.2016-1067 (2017).","journal-title":"Endocr. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95583-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:28:15Z","timestamp":1743434895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95583-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95583"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95583-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4562120\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the relevant guidelines and regulations of the Declaration of Helsinki. The Institutional Review Board (IRB) of Severance Hospital in Seoul, Republic of Korea (IRB No: [4-2024-0367]) approved the study. The IRB, recognizing the sole academic nature of the investigators\u2019 database access and the absence of personally identifiable information utilization, exempted the need for obtaining written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Korea National Health Insurance Service-National Sample Cohort (NHIS-NSC) is a public open-access database. It is based on the health insurance claims data of all Koreans, and the sample cohort is available for public purposes and scientific research. The sample cohort data are available after approval for use by the National Health Insurance Service (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}],"article-number":"10962"}}